Skip to main content

Table 1 Characteristics of patients before treatment of nivolumab

From: Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study

Variables

n = 58

No. (%)

Sex

 Male

45 (78%)

 Female

13 (22%)

Age (years) (Median, Range)

66 (38–82)

ECOG performance status

 0

8 (14%)

 1

36 (62%)

 2

12 (21%)

 3

2 (3%)

Disease status

 Metastatic

43 (74%)

 Relapsed

15 (26%)

Primary site

 Gastric

49 (84%)

 Esophagogastric junction

9 (16%)

Histological type

 Intestinal type

34 (59%)

 Diffuse type

24 (41%)

HER-2 status

 Positive

13 (22%)

Site of metastases

 Lymph nodes

41 (72%)

 Peritoneum

27 (47%)

 Liver

20 (34%)

 Lung

12 (21%)

 Bone

9 (16%)

 Other

7 (12%)

Organs with metastasis

 1

17 (29%)

 2

24 (42%)

 3

13 (22%)

  ≥ 4

4 (7%)

Previous treatment regimens

 2

35 (60%)

 3

18 (31%)

  ≥ 4

5 (9%)

Previous therapies

 Pyrimidine analogs

56 (97%)

 Platinum

50 (86%)

 Taxane

55 (95%)

 Ramucirumab

48 (83%)

 Trastuzumab

11 (19%)

 Irinotecan

16 (28%)

Treatment period before nivolumab (months)

14.9 (4.9–64.6)

Immune-related adverse events

 Positive

10 (17%)